Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 820 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... September 18, 2019 Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 EMA Recommends Extending the Indications for Dostarlimab October 17, 2023 Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Load more HOT NEWS After a Breast Cancer Diagnosis, Men May Be More Likely to... Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers
